Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Total Current Assets : $48.88 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Clarus Therapeutics Holdings's total current assets for the quarter that ended in Jun. 2022 was $48.88 Mil.

Clarus Therapeutics Holdings Total Current Assets Historical Data

The historical data trend for Clarus Therapeutics Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Total Current Assets Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Total Current Assets

19.34

51.64

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Current Assets	Get a 7-Day Free Trial			-	45.26	51.64	36.46	48.88

Clarus Therapeutics Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Clarus Therapeutics Holdings's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	26.415	+	6.341	+	14.214	+	4.673
	=	51.64

Clarus Therapeutics Holdings's Total Current Assets for the quarter that ended in Jun. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	19.173	+	8.705	+	16.805	+	4.197
	=	48.88

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Clarus Therapeutics Holdings's Liquidation Value for the quarter that ended in Jun. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	19.173	-	62.003	+	0.75 * 8.705	+	0.5 * 16.805
=	-27.90

Clarus Therapeutics Holdings Total Current Assets Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402